These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15490379)

  • 1. Ibandronate in metastatic bone pain.
    Heidenreich A; Ohlmann C; Body JJ
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):67-72. PubMed ID: 15490379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
    Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
    Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.
    Tripathy D; Body JJ; Bergström B
    Clin Ther; 2004 Dec; 26(12):1947-59. PubMed ID: 15823760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.
    Tripathy D; Lichinitzer M; Lazarev A; MacLachlan SA; Apffelstaedt J; Budde M; Bergstrom B;
    Ann Oncol; 2004 May; 15(5):743-50. PubMed ID: 15111341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing metastatic bone disease: three case studies.
    Coleman R; Heidenreich A; Bell R
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):83-6. PubMed ID: 15490382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibandronate reduces skeletal morbidity in patients with breast cancer.
    Tripathy A D; Diel I; Body JJ
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):64-6. PubMed ID: 15490378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.
    Body JJ; Diel IJ; Lichinitzer M; Lazarev A; Pecherstorfer M; Bell R; Tripathy D; Bergstrom B
    Br J Cancer; 2004 Mar; 90(6):1133-7. PubMed ID: 15026791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.
    Diel IJ; Body JJ; Lichinitser MR; Kreuser ED; Dornoff W; Gorbunova VA; Budde M; Bergström B;
    Eur J Cancer; 2004 Jul; 40(11):1704-12. PubMed ID: 15251160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer.
    Body JJ; Diel IJ; Bell R; Pecherstorfer M; Lichinitser MR; Lazarev AF; Tripathy D; Bergström B
    Pain; 2004 Oct; 111(3):306-312. PubMed ID: 15363874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study.
    Mancini I; Dumon JC; Body JJ
    J Clin Oncol; 2004 Sep; 22(17):3587-92. PubMed ID: 15337809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing metastatic bone pain: the role of bisphosphonates.
    Gralow J; Tripathy D
    J Pain Symptom Manage; 2007 Apr; 33(4):462-72. PubMed ID: 17397707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment.
    Bauss F; Bergström B
    Curr Clin Pharmacol; 2008 Jan; 3(1):1-10. PubMed ID: 18690873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibandronate: its role in metastatic breast cancer.
    Cameron D; Fallon M; Diel I
    Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibandronate: efficacy in the treatment of metastatic bone disease.
    Diel IJ
    Future Oncol; 2005 Oct; 1(5):593-607. PubMed ID: 16556036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer.
    Macpherson IR; Bray C; Hopkins C; Hannon RA; Lewsley LA; Ritchie DM; Canney P
    Clin Breast Cancer; 2015 Apr; 15(2):117-27. PubMed ID: 25454689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ibandronate in the treatment of neoplastic bone disease.
    Pecherstorfer M
    Expert Opin Pharmacother; 2004 Nov; 5(11):2341-50. PubMed ID: 15500381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ibandronate in metastatic bone disease: review of clinical data.
    Bell R
    Oncologist; 2005; 10 Suppl 1():8-13. PubMed ID: 16264107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover.
    Ringe JD; Body JJ
    Clin Exp Rheumatol; 2007; 25(5):766-74. PubMed ID: 18078631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer.
    Hoskin P; Sundar S; Reczko K; Forsyth S; Mithal N; Sizer B; Bloomfield D; Upadhyay S; Wilson P; Kirkwood A; Stratford M; Jitlal M; Hackshaw A
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26242893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.